Search the Newsreel

Uniphar Flags Higher H1 Earnings

Innate Pharma SA (IPHA) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Innate Pharma SA (IPHA), focusing on support, resistance, indicators, and moving averages. It summarizes various technical indicators like MACD, RSI, and KDJ, alongside moving averages (MA5 to MA200), to give a current market sentiment for the stock. …

Innate Pharma SA (IPHA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey focuses on Innate Pharma SA's (IPHA) revenue breakdown, noting that relevant data regarding business segments and regional revenue has not yet been disclosed by the company. It provides current stock information for IPHA, including its market cap and recent stock …

Innate Pharma (Nasdaq: IPHA) finishes Phase 1 IPH4502 dose escalation

Innate Pharma (Nasdaq: IPHA) has completed enrollment in the dose-escalation part of its Phase 1 IPH4502-101 study, involving 76 patients with advanced solid tumors. The study evaluates IPH4502, a Nectin-4 exatecan antibody-drug conjugate, showing a favorable safety profile and preliminary anti-tumor activity. Preliminary data …

Innate Pharma SA (IPHA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Innate Pharma SA (IPHA), listing its major shareholders and their proportions, including AstraZeneca PLC, Lion Point Capital, L.P., and Morgan Stanley & Co. International Plc. It also breaks down shareholder types and provides a history of institutional …

Why Medipharm Labs Corp stock is plummeting today

Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference

Innate Pharma SA will participate in a bladder cancer panel discussion titled "Changing Treatment Landscape in Bladder Cancer" at the BTIG Virtual Biotechnology Conference on July 28, 2026. Sonia Quaratino, EVP Chief Medical Officer, will represent the company, which specializes in developing immunotherapies for …

Innate Pharma (Nasdaq: IPHA) to speak on BTIG bladder cancer panel

Innate Pharma S.A. announced that its EVP Chief Medical Officer, Sonia Quaratino, will participate in the "Changing Treatment Landscape in Bladder Cancer" panel at the BTIG Virtual Biotechnology Conference 2026. The panel is scheduled for July 28, 2026, at 10:30 a.m. EDT. Innate Pharma, …

Innate Pharma: Medical Director to Lead BTIG Panel on Bladder Cancer

Innate Pharma's medical director, Sonia Quaratino, will lead a panel discussion on the evolving treatment landscape for bladder cancer at the BTIG Virtual Biotechnology Conference on July 28, 2026. This participation highlights Innate Pharma's involvement in immuno-oncology, including its clinical program for IPH4502, an …

Innate Pharma concludes enrolment in dose escalation of IPH4502 study

Innate Pharma has completed patient enrollment for the dose escalation segment of its Phase I IPH4502-101 study. This study investigates the safety, tolerability, and preliminary anti-tumor activity of IPH4502, a Nectin-4 exatecan antibody-drug conjugate, in patients with advanced solid tumors. The company anticipates preliminary …

IPHA Q1 2026 Earnings: EPS Miss Draws Attention as Stock Rises Despite No Revenue - Earnings Growth Analysis

Innate Pharma completes Phase 1 dose escalation enrollment

Innate Pharma has completed patient enrollment for the dose escalation phase of its Phase 1 study for IPH4502, a Nectin-4 targeting drug for advanced solid tumors. The study, involving 76 patients, has shown a favorable safety profile. Preliminary clinical data is expected by the …

Innate Pharma Completes Dose Escalation of IPH4502, Results Expected by End of 2026

Innate Pharma has completed the dose escalation phase of its Phase 1 study for IPH4502, an antibody-drug conjugate targeting Nectin-4. The drug has demonstrated a favorable tolerance profile with limited hematologic toxicity and observed antitumor activity in heavily pretreated patients with advanced solid tumors. …

Innate Pharma completes enrollment in IPH4502 phase 1 study

Innate Pharma has completed enrollment for the dose escalation portion of its Phase 1 study for IPH4502, an investigational Nectin-4 antibody-drug conjugate. The study involved 76 patients with advanced solid tumors, and Innate Pharma expects to release preliminary data by the end of the …

Innate Pharma's IPH4502 Reports Responses in Three Tumor Types

AnalystConsensusTarget updated the narrative for IPH on Apr 09 2025

AnalystConsensusTarget has updated its narrative for Innate Pharma (IPH), citing clinical trial enrollment and FDA designation as key factors for oncology opportunities. The fair value for IPH increased by 15%, with the company currently deemed 71.8% undervalued. AnalystConsensusTarget also adjusted several financial metrics, including …

At €4.78, Is It Time To Put Uniphar plc (ISE:UPR) On Your Watch List?

Uniphar plc (LON:UPR) Slides on Low Volume in FTSE AIM 100

Revenue at Uniphar grows 11% as it tops €3.1bn

Healthcare services firm Uniphar records strong 2025 with revenue hitting €3bn

Best performing stock: Uniphar tops the Iseq after strongest organic growth since IPO

Uniphar on track for €200m earnings target

Uniphar's 2025 earnings per share beat expectations

Is Uniphar’s Rare-Disease Logistics Expansion with Zevra Reshaping the Investment Case for Uniphar (ISE:UPR)?

Uniphar plc's (ISE:UPR) market cap dropped €53m last week; individual investors who hold 50% were hit as were institutions

Uniphar plc's (ISE:UPR) Business Is Trailing The Market But Its Shares Aren't

Uniphar sees profits rise to €38m as growth accelerates

Uniphar flags profit growth for first half of the year

Uniphar's H1 earnings per share growth beat forecasts

Revenue rises 23.3pc at healthcare services group Uniphar

Uniphar plc: Shareholders Board Members Managers and Company Profile | IE00BJ5FQX74